Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients
- 71 Downloads
Oral vitamin K antagonists (VKAs) are commonly used in older adults. To ensure the efficiency and safety of these drugs, the international normalized ratio (INR) must be monitored. The time in therapeutic range (TTR) is an internationally recommended assessment of the anticoagulation quality.
Our study aimed to assess the TTR of VKAs in a hospitalized geriatric population and identify factors associated with low TTR.
This was a multicenter retrospective study of data from 1899 patients with a mean age of 87 years between 2013 and 2015 in the geriatric units of four French hospitals. The data collection consisted of 2450 VKA prescriptions. We excluded prescriptions with a duration of < 7 days, monitoring with fewer than two INR values and patients with prosthetic heart valves. TTR was assessed using the Rosendaal method. Factors associated with a low TTR (< 50%) were assessed using a non-parametric method.
The mean TTR observed in this population was 42.6%. The TTR was < 50% for 62.5% of the patients included in this study. Significant associations were found between TTR < 50% and aspartate transaminase (AST), alkaline phosphatase (ALT), thyroid-stimulating hormone (TSH), prescription duration, fluconazole instauration, hemoglobin, and C-reactive protein (CRP).
Both our results and those in the literature indicate that TTR in geriatric populations is lower than that in the general population. Most patients had an insufficient TTR, exposing them to an increased risk of thromboembolic and hemorrhagic events. These data provide a perspective on poor-quality anticoagulation and illustrates the difficulty of using VKAs in geriatric patients.
Study concept and design: LL, FK, AB-K, NC, LS, BF, MD, LB. Analysis and interpretation of data: LL, FK, LB, MD. Preparation, revision, and approval of the manuscript: LL, FK, ABK, NC, LS, BF, MD, LB.
Compliance with ethical standards
Conflicts of interest
LL, FK, AB-K, NC, LS, BF, MD, and LB have no conflicts of interest that might be relevant to the contents of this manuscript.
No external funding was used in the preparation of this manuscript.
- 3.Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101–98.CrossRefPubMedGoogle Scholar
- 13.Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation A multicenter study of its status and infuential factors. Circ J Off J Jpn Circ Soc. 2011;75(9):2087–94.Google Scholar
- 16.January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRefPubMedGoogle Scholar
- 17.Lehto M, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Hoti F, et al. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Pharmacoepidemiol Drug Saf. 2017;26(6):657–65.CrossRefPubMedGoogle Scholar
- 19.Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet Lond Engl. 2007;370(9586):493–503.CrossRefGoogle Scholar
- 25.Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166–76.CrossRefPubMedGoogle Scholar
- 26.Chan P-H, Li W-H, Hai J-J, Chan EW, Wong ICK, Tse H-F, et al. Time in therapeutic range and percentage of international normalized ratio in the therapeutic range as a measure of quality of anticoagulation control in patients with atrial fibrillation. Can J Cardiol. 2016;32(10):1247.e23–8.Google Scholar
- 28.Ritschel WA. Handbook of basic pharmacokinetic, including clinical applications. Hamilton: Drug Intelligence Publications; 1986.Google Scholar
- 29.Wolfgang RA, Ritschel WA. Gerontokinetics: pharmacokinetics of drugs in the elderly. 1st edn. Telford:Telford Press; 1988.Google Scholar